Testing confirms response failure to genomic biomarker-directed therapy

Patient Profile

• 86-year-old woman with metastatic non-small cell lung cancer and confirmed MET Exon 14 skipping mutation 

• Matched to a targeted therapy (capmatinib) based on sequencing and the identification of a targeted mutation (in her MET gene).  

• Oncologist started targeted therapy, initially with successful results. 

• Therapy worked for approximately 9 months (Aug 2020 to March 2021). 

• Oncologist suspected cancer was becoming resistant to capmatinib, based on her development of a malignant pleural effusion, and wanted confirmation.

Travera Testing

• Tumor cells were isolated from a malignant pleural effusion specimen.

• Travera tested capmatinib against patient’s malignant cells.

Results

•  Travera test results confirmed the oncologist's suspicion that patient’s cancer cells were resistant to capmatinib.